Following a child deaths scandal tied to cough syrup, Indian authorities declined requests from pharmaceutical manufacturers for an extension to upgrade plants to meet international standards by year-end. Health ministry and regulatory bodies insisted that deadlines be met to ensure patient safety and restore export credibility. Several firms expressed concern over timelines and cost burdens. The move signals government resolve and regulatory risk ahead. Market watchers expect impacted pharma names to face revaluation pressure depending on capital spend and compliance stories.